Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study reports significant improvements in joint pain and hair regrowth in a 31-year-old female with alopecia universalis, psoriasis vulgaris, and psoriatic arthritis using a combination of tofacitinib and methotrexate after other treatments failed.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

This review summarizes the therapeutic potential and development of engineered extracellular vesicles for tissue repair and regenerative medicine, reporting no new clinical findings.

In this study, oral tofacitinib was associated with significant hair regrowth in patients with alopecia areata, achieving over 50% reduction in Severity of Alopecia Tool scores, with mild side effects.

This study observed that oral administration of BeauTop, a Chinese herbal medicine, significantly increased hair growth indicators, including VEGF expression, hair follicles, and hair coverage in C57BL/6 mice.

This study reported that the novel topical serum REVIVV®, containing a blend of phytochemicals, significantly improved hair growth and reduced shedding in 150 participants with androgenetic alopecia after 8 weeks of use, while also being rated easy to use and prompting plans for continued use.

This study found that TRP-hair essence significantly protected and improved the quality of human hair, particularly against heat stress, by enhancing cuticle health and maintaining hair color.

This study found that Botryococcus terribilis ethanol extract significantly reduced inflammation markers in LPS-stimulated RAW264 cells, potentially via Axl inhibition and alteration of immune-related gene expression.

This study reported that tofacitinib may be a promising treatment for alopecia areata in adolescents, showing significant hair regrowth with mild adverse effects in a retrospective review.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

The article in Dermatologic Therapy discusses clinical experiences with using tofacitinib to treat alopecia areata in 63 patients, but no specific results are reported in the abstract.

This study found that oral etretinate improved skin conditions like erythrodermic and pustular psoriasis, although less so for psoriasis vulgaris and lichen planus, with notable side effects including cheilitis and mucous membrane dryness.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

This study found that oral tofacitinib at a 5mg twice daily dosage was effective in treating recalcitrant alopecia areata, showing significant improvement in hair regrowth and a 27% reduction in SALT scores over six months, with minimal side effects among the 19 patients monitored.

In this case report, a young female Indian patient with alopecia areata saw hair regrowth within 2 months of treatment with oral tofacitinib, with continued improvements over a 5-month period and no reported side effects.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.

This study observed that combining PRP and Tressfix Serum significantly improved hair regrowth and reduced microRNA expression linked to Chronic Telogen Effluvium compared to using either treatment alone.

This study reported the development of a novel and reliable liquid chromatographic method to measure testosterone and epitestosterone in human urine, offering sensitive detection for doping control.

In this retrospective study, tofacitinib was found to be effective and well-tolerated for treating severe alopecia areata, with 77% of patients achieving a clinical response over 4-20 months, though results were more favorable for patients with less extensive hair loss.

This article describes acute and chronic telogen effluvium, highlighting the importance of differentiating them from androgenetic alopecia for accurate diagnosis and treatment strategies but includes no new clinical research findings.

This study in Mexican adolescents with severe alopecia areata reported that oral tofacitinib treatment resulted in hair growth and reduced alopecia severity without serious adverse effects.

This review highlights the potential of drug-loaded extracellular vesicles as a promising drug delivery platform but notes that clinical translation faces challenges due to variability in methods and the need for standardization and safety evaluation.

This study found that arginine vasotocin is evolutionarily conserved across diverse taxa and may play roles in neuroendocrine, immune, and stress signaling, with potential antimicrobial applications.

This study discusses the role of CD8+ T-cell and interferon γ signaling in vitiligo's pathogenesis and notes that JAK inhibitors, which are FDA-approved for other autoimmune diseases, may offer a potential treatment path by blocking this pathway.

In this preclinical study, researchers developed and evaluated a new non-invasive laser system designed for personalized medical use, showing its potential for chronic disease management and adjunctive fat reduction by offering enhanced treatment precision and adaptability over existing devices.

This study found that persistent significant alopecia was a common side effect following FEC-docetaxel chemotherapy, with a 33.4% global incidence, highlighting the need for awareness and potential preventative measures like cooling caps during treatment.

This review describes the diagnosis and management challenges of telogen effluvium, a type of hair loss triggered by physiological stress, and summarizes current understanding of its mechanisms and treatments while recommending future research directions.

This study found that oral tofacitinib was effective in promoting hair regrowth in patients with alopecia universalis, although further controlled studies are recommended to confirm its safety and efficacy.